Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.32 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20647932 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL19223302 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL18636581 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL18636579 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL23034636 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL23685889 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL19223102 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL18636609 | 1.00 | CYP3A4 (0.35) | CYP3A4CYP2C9KRASBTN3A1POLRMT | |
| SCHEMBL21283656 | 0.94 | CYP3A4 (0.37) | CYP3A4CYP2C9BTN3A1POLRMT | |
| SCHEMBL22142954 | 0.94 | CYP3A4 (0.37) | CYP3A4CYP2C9BTN3A1POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000873-A1 | PHOSPHOLIPID FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11344565-B2 | Methods for the preparation of ribosides | GILEAD SCIENCES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3785717-B1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021262826-A2 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-12-23 | — | — | US | disclosed |
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20210330685-A1 | INHALATION FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. | 2021-10-28 | — | — | US | disclosed |
| WO-2021154687-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-11007208-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10696679-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10682368-B2 | Methods of treating feline coronavirus infections | GILEAD SCIENCES, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696679-B2 | Methods and compounds for treating paramyxoviridae virus infections | PNP, RPIA, HPRT1 | CYP3A4 1697/4885CYP2C9 3257/4885KRAS 2617/4885 |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885 |
| US-20190275063-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885KRAS 4427/4885 |
| US-11007208-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885 |
| US-20230000873-A1 | PHOSPHOLIPID FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | PHOSPHO1, SGMS1, PCYT1A | CYP3A4 2254/4885CYP2C9 1363/4885KRAS 999/4885 |
| US-11344565-B2 | Methods for the preparation of ribosides | RUVBL2, RUVBL1, EIF2AK2 | CYP3A4 2996/4885CYP2C9 4188/4885KRAS 2335/4885 |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885 |
| US-20190255085-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885 |
| US-20210393659-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885 |
| US-10251898-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | CYP3A4 772/4885CYP2C9 2974/4885KRAS 4427/4885 |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CYP3A4 1145/4885CYP2C9 2167/4885KRAS 3720/4885 |
| US-10682368-B2 | Methods of treating feline coronavirus infections | SARS1, CPN1, CAT | CYP3A4 1929/4885CYP2C9 4334/4885KRAS 1893/4885 |
| US-20200197422-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | CYP3A4 2895/4885CYP2C9 4593/4885KRAS 3372/4885 |
| US-20210330685-A1 | INHALATION FORMULATIONS OF 1'-CYANO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | SLC29A1, SLC28A1, SLC29A2 | CYP3A4 1147/4885CYP2C9 633/4885KRAS 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.